Navigation Links
Boston Scientific to Participate in Merrill Lynch Conference
Date:1/30/2008

NATICK, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 5-7 in New York City.

Paul LaViolette, Chief Operating Officer, will make a 40-minute presentation on Wednesday, February 6, beginning at approximately 10:20 a.m. E.T. Sam Leno, Executive Vice President and Chief Financial Officer will join Mr. LaViolette in a question and answer session.

A live webcast of Mr. LaViolette's remarks and the question and answer session will be available to all interested parties at Boston Scientific's website at http://www.bostonscientific.com. Please visit the website for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins.

This webcast is being hosted by Merrill Lynch. The replay will be archived and available in the Investor Relations site at http://www.bostonscientific.com.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
2. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
4. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
5. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
6. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
7. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Genzyme Begins Major Expansion of Boston Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... San Antonio, TX (PRWEB) , ... February 23, ... ... and Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, ... is indicated for adults at home or in healthcare facilities during periods of ...
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 non-profit, ... is to advance global health and highlight the greater good of clinical trial participation ... trial volunteer. The vision of GGI is to serve as a philanthropic connector between ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):